Sign in

Private company

LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Co., Ltd. is a pharmaceutical preparations company in the Cayman Islands.1 It is headquartered in Beijing, China.1

Last updated Oct 21, 2026.

Overview

$85.7MRevenue, fiscal 20252
-$13.9MNet income, fiscal 20252
  • IndustryPharmaceutical Preparations1
  • HeadquartersBeijing, China1
  • Incorporated inCayman Islands3
  • Business addressBuilding No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, F4 1026293
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Phase I trial among 37 healthy volunteer subjects in Singapore, completed in February 2016;4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

82.5%Gross margin2
-14.0%Operating margin2
-16.3%Net margin2
6.0%Revenue growth, 20252
-20.0%Return on equity2
0.05×Debt to equity2
-$18.6MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue18¢$15.0M
  • Research and development24¢$20.4M
  • Other costs59¢$50.1M
  • Income tax0¢$131.9K

Out of $85.7M in revenue.2 The company lost money this year.

Financial statements

Revenue562$85.7M in 2025−14% since 2023
0$50.0M$100.0M$150.0M2023: $100.0M$100.0M20232024: $80.8M$80.8M2024−19%2025: $85.7M$85.7M2025+6%
Gross profit562$70.7M in 2025−9% since 2023
0$20.0M$40.0M$60.0M$80.0M2023: $77.7M$77.7M20232024: $64.2M$64.2M2024−17%2025: $70.7M$70.7M2025+10%
Operating income562-$12.0M in 2025−41% since 2023
-$80.0M-$60.0M-$40.0M-$20.0M02023: -$20.3M-$20.3M20232024: -$62.8M-$62.8M2024+210%2025: -$12.0M-$12.0M2025−81%
Net income562-$13.9M in 2025−34% since 2023
-$80.0M-$60.0M-$40.0M-$20.0M02023: -$21.2M-$21.2M20232024: -$61.1M-$61.1M2024+189%2025: -$13.9M-$13.9M2025−77%
Fiscal year2022202320242025
Revenue$100.0M5$80.8M6$85.7M2
Cost of revenue$22.3M5$16.6M6$15.0M2
Gross profit$77.7M5$64.2M6$70.7M2
Research and development$46.4M5$42.7M6$20.4M2
Operating expenses$98.0M5$127.1M6$82.7M2
Operating income-$20.3M5-$62.8M6-$12.0M2
Income before tax-$21.0M5-$64.2M6-$14.1M2
Income tax$165.0K5-$3.1M6-$131.9K2
Net income-$21.2M5-$61.1M6-$13.9M2
Earnings per share-$0.235-$0.576-$0.732
Earnings per share (diluted)-$0.235-$0.576-$0.732
Shares (weighted, basic)61.8M shares66.2M shares210.7M shares219.2M shares2
Shares (weighted, diluted)61.8M shares66.2M shares210.7M shares219.2M shares2

Compare LakeShore Biopharma Co., Ltd. with another company

Corporate structure

LakeShore Biopharma Co., Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LakeShore Biopharma Co., Ltd.

  • Crystal Peak Investment Inc. Filed SCHEDULE 13D/A on LakeShore Biopharma Co., Ltd., latest Jun 25, 2026 (8 filings since Jul 22, 2025)
  • Fung Ching Wong Filed SCHEDULE 13D/A on LakeShore Biopharma Co., Ltd., latest Jul 15, 2025 (2 filings since Feb 14, 2024)
  • /md Yi Zhang Filed SC 13G/A on LakeShore Biopharma Co., Ltd., latest Feb 16, 2024 (2 filings since Feb 15, 2024)
  • LakeShore Biopharma Co., Ltd. Beijing, China

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LakeShore Biopharma Co., Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$102.1M2 Mar 31, 2025$111.2M6 Mar 31, 2024−8.2%
Accumulated depreciation$26.7M2 Mar 31, 2025$29.0M6 Mar 31, 2024−7.8%
Property and equipment, net$57.6M2 Mar 31, 2025$66.7M6 Mar 31, 2024−13.7%
Operating-lease assets (leased space)$118.0K2 Mar 31, 2025$1.0M6 Mar 31, 2024−88.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$10.1M2 Mar 31, 2025$10.0M6 Mar 31, 2024+1.1%
Finite-lived intangibles, gross$24.6M2 Mar 31, 2025$22.2M6 Mar 31, 2024+10.8%
Accumulated amortization$13.0M2 Mar 31, 2025$12.1M6 Mar 31, 2024+7.0%
Finite-lived intangibles, net$10.1M2 Mar 31, 2025$10.0M6 Mar 31, 2024+1.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$31.7M2 Mar 31, 2025$28.7M6 Mar 31, 2024+10.6%
Raw materials$5.1M2 Mar 31, 2025$9.7M6 Mar 31, 2024−47.3%
Work in process$8.1M2 Mar 31, 2025$6.9M6 Mar 31, 2024+17.0%
Finished goods$22.8M2 Mar 31, 2025$21.7M6 Mar 31, 2024+5.3%

Leadership

Who has led LakeShore Biopharma Co., Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Xu Wang2026–now

President

  1. Hui David Shao2026–now

Chief financial officer

  1. Rui Yu2026–now
Board members and other officers (7)

Former names

  • YS Biopharma Co., Ltd.Oct 31, 2022 to May 24, 20243
  • YishengBio Co., LtdSep 29, 2022 to Feb 21, 20233

Timeline

  1. Apr 10, 2026New chief executive Xu Wang becomes CEO7

Filings

151 filings to the SEC since October 2021: 3 annual reports, 7 insider forms, 12 large holders, 129 other. The latest 20:

  1. Jun 25, 2026SCHEDULE 13D/A EDGAR
  2. Jun 24, 202615-12G EDGAR
  3. Jun 24, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 EDGAR
  4. Jun 24, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 EDGAR
  5. Jun 24, 2026SC 13E3/A AMENDMENT NO. 8 TO SCHEDULE 13E-3 EDGAR
  6. Jun 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Jun 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. May 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. May 28, 2026SC 13E3/A AMENDMENT NO. 7 TO SCHEDULE 13E-3 EDGAR
  10. May 8, 2026SC 13E3/A AMENDMENT NO. 6 TO SCHEDULE 13E-3 EDGAR
  11. Apr 29, 2026SCHEDULE 13D/A EDGAR
  12. Apr 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Apr 10, 20263 EDGAR
  14. Apr 10, 20263 EDGAR
  15. Apr 1, 20263 OWNERSHIP DOCUMENT EDGAR
  16. Apr 1, 20263 OWNERSHIP DOCUMENT EDGAR
  17. Apr 1, 20263 OWNERSHIP DOCUMENT EDGAR
  18. Apr 1, 20263 OWNERSHIP DOCUMENT EDGAR
  19. Apr 1, 2026SC 13E3/A AMENDMENT NO. 5 TO SCHEDULE 13E-3 EDGAR
  20. Mar 31, 20263 EDGAR

The 151 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Crystal Peak Investment Inc.SCHEDULE 13D/A, 8 filings Jul 22, 2025 to Jun 25, 202614
  • Fung Ching WongSCHEDULE 13D/A, 2 filings Feb 14, 2024 to Jul 15, 202515
  • /md Yi ZhangSC 13G/A, 2 filings Feb 15, 2024 to Feb 16, 202416

SEC filer profile

How LakeShore Biopharma Co., Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLakeShore Biopharma Co., Ltd.1
  • CIK0001946399
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressBuilding No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, F4 1026291
  • Phone173271336781
  • Shares outstanding20,766,531 shares as of Mar 31, 20254
  • AuditorGrant Thornton Zhitong Certified Public Accountants LLP, Shanghai, China PCAOB ID 1487; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 29, 20221
  • Filings156 in all: 6-K (71), 424B3 (9), SC 13E3/A (8), SCHEDULE 13D/A (8), 3 (7), CORRESP (6), UPLOAD (6), 425 (4)1
    All 31 form types

    EFFECT (4), 20-F (3), DRSLTR (3), F-4/A (3), S-8 POS (3), DRS/A (2), POS AM (2), S-8 (2), 15-12G (1), 25-NSE (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1/A (1), F-4 (1), NT 20-F (1), SC 13D (1), SC 13E3 (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Jul 31, 2025

Securities registered for trading

ClassSymbolExchange
Ordinary share, par value US$0.0002 per shareLSBNasdaq
Warrants, each exercisable for one ordinary shareLSBPWNasdaq

From the cover page of the 20-F filed Jul 31, 2025 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16